GlassScriptPhysician profile
Clayton T Buback
NPI 1598228231
$7,628.96
in general payments reported to CMS, 2019-2025
28 companies · $6,862 in 2025
The $6,862 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $767 · 2025: $6,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Food and Beverage: $2,601 · Travel and Lodging: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Food and Beverage | $2,600.63 |
| Travel and Lodging | $1,028.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $5,335.72 | 2024-2025 | Vyvgart Hytrulo |
| Ucb, INC. | $466.67 | 2024-2025 | Fintepla, Rystiggo, Briviact |
| Neurelis, INC. | $237.26 | 2024-2025 | Valtoco |
| Sk Life Science, INC. | $199.91 | 2024-2025 | |
| Genentech USA, INC. | $159.01 | 2024-2025 | Ocrevus Zunovo, Enspryng |
| Tg Therapeutics, INC. | $126.10 | 2025 | |
| Biogen, INC. | $124.21 | 2024-2025 | Tysabri, Vumerity, Skyclarys |
| Acadia Pharmaceuticals INC | $94.07 | 2024-2025 | Nuplazid, Daybue |
| Alexion Pharmaceuticals, INC. | $88.99 | 2024-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $87.41 | 2024-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $86.43 | 2025 | |
| Lundbeck LLC | $85.08 | 2024-2025 | Vyepti |
| Eisai INC. | $69.45 | 2024-2025 | |
| Csl Behring | $55.50 | 2024-2025 | Hizentra |
| Merz Pharmaceuticals, LLC | $52.69 | 2025 | Xeomin, Inbrija, Ampyra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $52.43 | 2024-2025 | |
| Emd Serono, INC. | $48.96 | 2025 | |
| Jazz Pharmaceuticals INC. | $47.64 | 2025 | |
| Amneal Pharmaceuticals LLC | $43.01 | 2024-2025 | Crexont, Brekiya |
| Neurocrine Biosciences, INC. | $32.66 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $29.76 | 2025 | Hyqvia |
| Pyros Pharmaceuticals, INC. | $19.07 | 2024 | Vigpoder |
| Axsome Therapeutics, INC. | $17.23 | 2025 | Symbravo |
| Biocodex, INC. | $15.32 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.86 | 2025 | Wainua |
| Xeris Pharmaceuticals, INC. | $13.81 | 2025 | Keveyis |
| Genzyme Corporation | $13.46 | 2025 | |
| Aucta Pharmaceuticals, INC. | $13.25 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clayton Buback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.